Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 16/20 | 0.39 |
| ▸ | CA2 | P00918 | 16/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL21567 | 0.93 | — | — | |
| Creatine SCHEMBL27979093 | 0.93 | NOS3 (0.46) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4007614 | 0.93 | NOS3 (0.46) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL30063981 | 0.93 | — | — | |
| Creatine SCHEMBL1241423 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL21404054 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL53010 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL21810557 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL20497169 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4269042 | 0.91 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-06-29 | — | — | US | disclosed |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-03-02 | — | — | US | disclosed |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019191338-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2019-10-03 | — | — | US | disclosed |
| US-7179477-B2 | Cosmetic dermabrasion treatment system | GUPTA SHYAM K | 2007-02-20 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20050037038-A1 | Cosmetic Dermabrasion Treatment System | GUPTA SHYAM K (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | NOS3 2825/4885NOS1 2319/4885NOS2 1479/4885 |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 4094/4885NOS1 4060/4885NOS2 3835/4885 |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.